elsubrutinib   Click here for help

GtoPdb Ligand ID: 10464

Synonyms: example #30 (S) [WO2014210255A1]
Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: Elsubrutinib (example #30 (S) [WO2014210255A1]) is the (S) stereoenantiomer of example #30 from Abbvie's patent WO2014210255A1 which claims BTK inhibitors for their potential to treat immunological and oncological conditions [1]. Example #30 (S) could be ABBV-105, an Abbvie BTK inhibitor that is being evaluated in combination with upadacitinib (ABT-494, a JAK1 inhibitor) in patients with rheumatoid arthritis or systemic lupus erythematosus (the combination is coded ABBV-599). Although preclinical efficacy has been reported [2], the structure of ABBV-105 has not been formally disclosed, so the name-to-structure alluded to here is speculative and provided in good faith.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 4
Hydrogen bond donors 2
Rotatable bonds 4
Topological polar surface area 79.19
Molecular weight 297.15
XLogP 1.86
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES C=CC(=O)N1CCCC(C1)c1ccc(c2c1cc[nH]2)C(=O)N
Isomeric SMILES C=CC(=O)N1CCC[C@H](C1)c1ccc(c2c1cc[nH]2)C(=O)N
InChI InChI=1S/C17H19N3O2/c1-2-15(21)20-9-3-4-11(10-20)12-5-6-14(17(18)22)16-13(12)7-8-19-16/h2,5-8,11,19H,1,3-4,9-10H2,(H2,18,22)/t11-/m1/s1
1. Bonafoux D, Davis HM, Frank KE, Friedman MM, Herold JM, Hoemann MZ, Huntley R, Osuma A, Sheppard G, Somal GK et al.. (2014)
Primary carboxamides as BTK inhibitors.
Patent number: WO2014210255A1. Assignee: Abbvie Inc.. Priority date: 26/06/2013. Publication date: 31/12/2014.
2. Goess C, Harris CM, Murdock S, McCarthy RW, Sampson E, Twomey R, Mathieu S, Mario R, Perham M, Goedken ER et al.. (2019)
ABBV-105, a selective and irreversible inhibitor of Bruton's tyrosine kinase, is efficacious in multiple preclinical models of inflammation.
Modern rheumatology, 29 (3): 510-522. [PMID:29862859]